Should statin therapy be routinely initiated in middle‑aged adults with at least one atherosclerotic cardiovascular disease risk factor and LDL‑C levels above 100 mg/dL? Observational data consistently shows that lower LDL-C and non-HDL-C levels are associated with substantially reduced risks of atherosclerotic vascular disease. In the absence of randomized trial data in younger and middle-aged adults with low 10–30 year risk, the role of additional risk stratification tools—such as hsCRP and coronary artery calcium scoring—becomes critical in guiding individualized decisions about when to begin lipid-lowering pharmacotherapy.

In this interview, William E. Boden MD, FACC and Roger S. Blumenthal, MD, FACC discuss ‘Lower LDL-C for Longer? Defining the Optimal Timing and Intensity of Rx’.

Related References:

1. Domanski MJ, Wu CO, Tian X, et al. Association of Incident Cardiovascular Disease With Time Course and Cumulative Exposure to Multiple Risk Factors. J Am Coll Cardiol. 2023;81(12):1151-1161. doi:10.1016/j.jacc.2023.01.024
2. Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis: evidence and practical applications. Nat Rev Cardiol. 2024;21(10):701-716. doi:10.1038/s41569-024-01039-5
3. Zheutlin AR, Handoo F, Luebbe S, et al. Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. Eur Heart J. 2025;46(41):4302-4312. doi:10.1093/eurheartj/ehaf472